YWYa-Qin Wang

Ya-Qin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ya-Qin Wang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Guan-Qun Zhou

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China

    2 shared publications
  • Chao-Feng Li

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

    1 shared publication
  • Chen-Yang Feng

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

    1 shared publication
  • Chen-Zhi Zhang

    1 shared publication
  • Chenglong Huang

    1 shared publication
  • Denghui Wei

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China

    1 shared publication

Latest Publications

  • Open Access

    A scalable AI framework for automated TNM staging of 51,242 patients with nasopharyngeal carcinoma

    by Zi-Cheng Zhen, Yu-Xue Qi, Ya-Qin Wang, Wei-Wei Zhang, Ji-Ming Xu, Song-Tao Liu, Xian-Yue Zeng, Guan-Qun Zhou, Chen-Yang Feng, Zeng-Tao Jiao, et al.

  • Open Access

    Body Mass Index as an Accessible Biomarker for Anti-PD-1 Immunotherapy Outcomes in Nasopharyngeal Carcinoma

    by Xiaoyue Zhang, Zi-Chen Qiu, Ze-Yu Zhang, Chenglong Huang, Yin Zhao, Gun-Qun Zhou, Chen-Zhi Zhang, Ya-Qin Wang

    Background: Obesity is a well-established risk factor and adverse prognostic indicator for multiple malignancies. Intriguingly, emerging evidence highlights an obesity paradox, wherein elevated body mass index (BMI) correlates with enhanced responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in several cancers. This study aimed to investigate the prognostic value and biological underpinnings of BMI in patients with nasopharyngeal carcinoma (NPC) receiving anti‑PD‑1 therapy.Methods: Enrolled patients were stratified based on BMI using Asian specific criteria. Survival analyses were performed to evaluate the prognostic efficacy of BMI, and a BMI-incorporated nomogram was constructed for individualized risk prediction. To elucidate the underlying mechanisms, integrated analysis of transcriptomic data (n=150) and digital pathology (n=161) were performed to systematically characterize BMI-specific tumor microenvironment (TME) features. Results: This retrospective study included 573 NPC patients who received anti‑PD‑1 therapy. Overweight and obese patients exhibited a significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to those with normal BMI. The BMI incorporated nomogram demonstrated superior predictive accuracy and robust clinical applicability. Furthermore, high-BMI tumors exhibited an inflamed yet immunosuppressive TME, characterized by enhanced CD8⁺ T cell infiltration, elevated expression of multiple immune checkpoint molecules including PD-L1, and unique alterations in core metabolic pathways.Interpretation: Higher BMI is associated with improved survival after anti‑PD‑1 treatment in NPC, possibly reflecting an immune‑inflamed tumor microenvironment that favors checkpoint blockade.

  • TEAD4 is a master regulator of high-risk nasopharyngeal carcinoma

    by Ya-Qin Wang, Dong-Hong Wu, Denghui Wei, Jia-Yi Shen, Zi-Wei Huang, Xiao-Yu Liang, William C.S. Cho, Jun Ma, Jiawei Lv, Yu-Pei Chen

    The molecular basis underlying nasopharyngeal carcinoma (NPC) remains unclear. Recent progress in transcriptional regulatory network analysis helps identify the master regulator (MR) proteins that transcriptionally define malignant tumor phenotypes. Here, we investigated transcription factor-target interactions and identified TEA domain transcription factor 4 (TEAD4) as an MR of high-risk NPC. Precisely, TEAD4 promoted NPC migration, invasion and cisplatin resistance, depending on its autopalmitoylation. Mechanistically, YTHDF2 (YTH domain family 2) recognized WTAP (Wilms tumor 1–associating protein)–mediated TEAD4 m 6 A methylation to facilitate its stability and led to aberrant up-regulation of TEAD4. Up-regulated TEAD4 further drove NPC progression by transcriptionally activating BZW2 (basic leucine zipper and W2 domains 2) to induce the oncogenic AKT pathway. Moreover, the transcriptional activity of TEAD4 was independent of its canonical coactivators YAP/TAZ. Clinically, TEAD4 serves as an independent predictor of unfavorable prognosis and cisplatin response in NPC. Our data revealed the crucial role of TEAD4 in driving tumor malignancy, thus, may provide therapeutic vulnerability in NPC.